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Abstract 
Objective: The aim of this study was to determine whether genetic variation at the cannabinoid 
receptor-1 (CNR1) locus could have an effect on adiposity, fat distribution and obesity-related 
metabolic disorders in Polish postmenopausal women. 
Design and Subjects: The A3813G,  G1422A and A4895G single nucleotide polymorphisms of 
CNR1 were genotyped in 348 randomly selected postmenopausal women aged 50-60 years recruited 
from the Wroclaw city population.  
Measurements: CNR1 genotypes, anthropometric measures (BMI, WC,  body fat distribution by 
DEXA) and metabolic parameters (glucose, lipid profile, insulin FIRI) were determined. 
Results: The 3813G allele was not significantly associated with higher body mass, BMI, WC, total 
fat, or fat percentage, but was associated with higher android fat deposit (2971.78 ± 1655.08 ± 2472.64 
± 1300.53, p = 0.007) and percentage of android fat (37.59 ± 8.45 vs. 35.66 ± 7.63, p = 0.062). The 
1422A allele was associated with higher total fat (31587.72 ± 9161.28 g vs. 26078.26 ± 7552.14 g, p = 
0.019), fat percentage (40.51 ± 5.66% vs. 37.51 ± 4.99%, p = 0.052), and percentage of android fat 
(40.86 ± 9.73% vs. 36.09 ± 7.70%, p = 0.047). No associations were observed for the A4895G variant. 
Conclusions: There is an association of variants of CNR1 with obesity-related phenotypes in Polish 
postmenopausal women. As CB1 is a drug target for obesity, pharmacogenetic receptor gene analysis 
of obesity treatment by endocannabinoid blockade may be of interest to identify the best responders. 
 Key words: CNR1 polymorphism, obesity, metabolic syndrome, postmenopausal women
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Introduction 
 Menopausal obesity is a multifactorial disease. The energy imbalance that results in 
menopausal obesity occurs as a result of genetic background, hormonal changes, and acquired changes 
in eating behavior and physical activity (1).  
The endocannabinoid system comprises two cannabinoid receptor subtypes, CB1 and CB2, 
their endogenous ligands and the enzymes for ligand biosynthesis and degradation (2). The CB1 
receptor, encoded by the CNR1 gene, has the greatest expression in the central nervous system but also 
in several peripheral organs including liver, muscle, and adipose tissue (3-6). Evidence suggests that 
CB1 and its endogenous ligands, the endocannabinoids, are involved in the regulation of energy 
balance, influencing feeding behavior and body weight (4-6). 
The endocannabinoid receptor type 1 gene, CNR1, is located on 6q14-q15. Several human 
CNR1 polymorphisms have been recently described in European-American, African- American, and 
Japanese individuals in association with polysubstance abuse (7). Thus polymorphic variants of this 
gene may contribute to individual differences in susceptibility to obesity, changes in body fat 
distribution, and related metabolic disorders. Russo et al. showed that genetic variants of CNR1 were 
associated with obesity related phenotypes in men (8), Peeters et al. demonstrated that G1422A 
polymorphism in the CNR1 gene was associated with increased abdominal adiposity in obese men (9) 
and Benzinou et al. showed that CNR1 variations increased the risk for obesity and modulated BMI in  
a European population (10). These observations led us to hypothesize that genetic variation at the 
cannabinoid receptor-1 (CNR1) locus could have an effect on adiposity, fat distribution and obesity-
related metabolic disorders in postmenopausal women. 
Materials and Methods 
 The study population consisted of  348 randomly selected postmenopausal women aged 50-60 
years (mean age 55.42±2.73 years) recruited from the Wroclaw city population with BMIs ranging 
from 17.5 to 46.38 kg/m2 (mean 27.48±4.78 kg/m2). Only women with a history of natural menopause 
not taking hormonal replacement therapy were included. None of the women smoked, were on special 
diets, or used medications influencing lipid profile or glucose metabolism. Women with diabetes 
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mellitus, previously recognized dyslipidemia, or liver dysfunction were excluded from the study. The 
patients were informed of the aim and the methods of the study and gave their informed consent in 
writing. The study protocol was approved by the Ethics Committee of Wroclaw Medical University, 
Poland. 
Anthropometric measurements 
 Anthropometric parameters, such as body mass, body height, and waist circumference were 
measured in all subjects. Body mass and height were measured to the nearest 0.1 kg, and height was 
measured to the nearest centimeter crown to heel without shoes. Waist circumference was measured at 
half distance between the costal angle and the iliac crests to the nearest 0.1 cm with a flexible 
inextensible plastic tape, with the subject standing straight with the abdomen relaxed, arms at the 
sides, and feet together. The body mass index (BMI) was calculated from the equation: body mass 
[kg]/height-squared [m2].  
The percentage of body fat and visceral fat deposit were assessed using the dual-energy X-ray 
absorptiometry (DXA) method using a DPX (+) Lunar device (USA). The percentage of abdominal fat 
(android fat deposit) was calculated using a computerized method after measuring fat tissue volume in 
the area between the upper edge of the L2 disc and the lower edge of the L4 disc. This region is 
characterized by a high amount of visceral and subcutaneous fat, which play a crucial role in insulin 
resistance and the development of metabolic syndrome (11,12).  
Biochemical measurements 
Blood for laboratory tests was collected between 7:00 and 9:00 a.m. after overnight fasting. 
Centrifuged serum for biochemical analyses and whole blood for genomic studies were stored until 
examination at -20°C. Serum concentrations of glucose (G), total cholesterol, HDL cholesterol, and 
triglycerides were measured by routine enzymatic methods (Olympus Au 560; bioMerieux, France). 
LDL cholesterol was calculated according to the Friedewald formula: cholesterol LDL [mg/dl] = total 
cholesterol [mg/dl] – HDL cholesterol [mg/dl] – (triglycerides [mg/dl]/5). The serum insulin (I) 
concentration was measured by a radioimmunological method using commercial kits (Diagnostic 
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Products Corporation, USA). For the estimation of insulin resistance, Fasting Insulin Resistance Index 
(FIRI) was calculated as fasting glucose [mmol/l] x fasting insulin [(mU/l]/25.  
Genetic studies 
Whole genomic DNA was isolated from blood leukocytes using standards methods. CNR1 genotyping 
(A3813G, G1422A, and A4895G) was performed by polymerase chain reaction (PCR) and 
minisequencing. 
To amplify the three fragments of CNR1 gene (347-bp, 346-bp, and 231-bp) was used multiplex PCR 
mix was employed containing: the specific three pairs of primers (see Table 1), 1x PCR buffer, 1.5mM 
MgCl2 , 200 μM dATP, 200 μM dCTP, 200 μM dGTP, 200 μM dTTP, 1x Q solution, 2 polymerase 
units (QIAGEN), 200 ng genomic DNA, and water for a total volume of 20 μl. 
The DNA was denatured at 95oC for 3 minutes followed by 35 cycles of denaturation at 95oC for 30 
seconds, annealing at 58oC for 30 seconds, and extension at 72oC for 45 seconds.  
The amplified fragments were purified from oligonucleotides and free dNTPs by SAP and ExoI 
treatment (Fermentas). 
The minisequencing method was based on the incorporation of single fluorescence-labeled 
dideoxynucleotides to the 3’ end of the oligonuclotide that was correctly paired to the specific 
template DNA fragment using a SNaPshot kit (Applied Biosystems). The SNaPshot reaction was 
carried out using the oligonucleotides:  
¾ A3813G: 5'-CTTGTTATGGTAGAAAAATTTCACG-3'  
¾ G1422A: 5'-TGCAGCCAGTGTTCACAGGGCCGCAGAAAGCTGCATCAAGAGCAC-3' 
¾ A4895G: 5'-TTAAGATGCCACGGCAATGTAAAGAAACTCTCCCA-3' 
designed so that it ended immediately before the polymorphic side .The  SNaPshot reaction consisted 
of 25 cycles: denaturation at 96oC for 10 seconds, annealing at 50oC for 5 seconds, and extension at 
60oC for 30 seconds. The product was analyzed by an ABI 310 sequencer (Applied Biosystems). 
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Statistical analysis 
Means and standard deviations of some physical and biochemical variables were calculated for 
genotypes of analysed polymorphisms. To compare means between genotypes the ANOVA and post-
hoc test (LSD) were used. Frequencies of risk factors in genotypes were compared by the chi-square 
test. 
Results 
We investigated, whether specific CNR1 polymorphisms are associated with anthropometric markers 
of obesity and fat distribution as well as parameters describing metabolic syndrome in Polish 
postmenopausal women.  
The A3813G polymorphism. Genetic analysis for this polymorphism was performed in 346 women. 
The AA genotype was found in 70%, AG in 22% and GG in only 8% of the women. The frequency of 
the A allele was p= 0.81 and of the G q= 0.19 (p+q=1). 
Because the GG genotype was present in only 8% of  the individuals, the analysis was performed 
according to the G dominant model (AG + GG vs. AA). The whole group was divided into two 
subgroups according to genotype (AG + GG vs. AA). The anthropometric and metabolic 
characteristics of these subgroups are presented in Tables 2 and 3. 
Although ANOVA analysis, adjusted for covariates, indicated that the G allele was associated 
with higher body mass, BMI, WC, total fat, and fat percentage, statistical significance was not 
observed. A significant positive association between the G allele and fat distribution  was observed, 
with the G allele carriers having significantly higher android fat deposit (2971.78 ± 1655.08 ± 2472.64 
± 1300.53, p = 0.007) and percentage of android fat (37.59 ± 8.45 vs. 35.66 ± 7.63, p = 0.062) (Table 
2). The latter difference did not achieve statistical significance. 
No significant association between genotype and metabolic parameters was observed (Table 3). 
The G1422A polymorphism. Genetic analysis for this polymorphism was performed in 333 women. 
The GG genotype was found in 62%, GA in 33% and AA in only 5% of the women. The frequency of 
the G allele was p= 0.79 and of the A q= 0.21 (p+q=1). 
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Because the AA genotype was present in only 5% of  the individuals, the analysis was performed 
according to the G dominant model (AG + AA vs. GG), and indicated no association between the 
genotypes and any of the quantitative variables investigated (data not shown). 
Analysis was also performed according to the A recessive model (AG + GG vs. AA). The whole group 
was divided into two subgroups according to genotype (AG + GG vs. AA). The anthropometric and 
metabolic characteristics of these subgroups are presented in Tables 4 and 5. 
ANOVA analysis, adjusted for covariates, indicated that the G allele was associated with lower body 
mass, although not statistically significantly. There were no differences in BMI between the 
subgroups, although it appeared that AA carriers were significantly taller, which could have affected 
differences in BMI. 
A significant positive association between the AA genotype and fat distribution was observed: the AA 
carriers had higher total fat (31587.72 ± 9161.28 vs. 26078.26 ± 7552.14 g, p = 0.019), fat percentage 
(40.51 ± 5.66% vs. 37.51 ± 4.99%, p = 0.052, on the border of statistical significance), and percentage 
of android fat (40.86 ± 9.73% vs. 36.09 ± 7.70%, p = 0.047). 
The A4895G polymorphism . Genetic analysis for this polymorphism was performed in all women 
studied. The AA genotype was found in 57%, AG in 33% and GG in 10% of the women. The 
frequency of the A allele was p= 0.74 and of the G q= 0.26 (p+q=1). 
No association was observed between the genotypes of the A4895G polymorphism and any of the 
quantitative variables investigated, whatever the genetic model, i.e. dominant or recessive (data not 
shown). 
Discussion 
Recent data suggest that the endocannabinoid system controls food intake via central, and 
lipogenesis via peripheral CB1 receptors (4-6). Pharmacological blockade of endocannabinoid 
receptor 1 leads to weight loss and an improved metabolic risk profile in overweight and obese 
individuals (13-15). Thus it was hypothesized that genetic variation at the cannabinoid receptor-1 
(CNR1) locus could have an effect on adiposity. Many investigators have suggested than an 
association exists between various CNR1 gene polymorphisms and parameters of obesity in various 
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populations (8,9,10,16,17). On the other hand, Lieb et al. who studied 18 single-nucleotide 
polymorphisms in the CNR1 gene in 2415 Framingham Offspring Study participants, found no 
evidence for an association of CNR1 polymorphisms with BMI, waist circumference, or visceral or 
subcutaneous adipose tissue (18). 
In our study, we examined three CNR1 polymorphisms:  A3813G, G1422A and A4895G. We 
observed that the G allele of the A3813G polymorphism was associated with higher body mass, BMI, 
WC, total fat, and fat percentage, although the differences were not statistically significant. 
Furthermore, G allele carriers had significantly higher android fat deposit. Similar observations were 
made in Italian and English men by Russo et al. (8), and in a French population by Benzinou et al. 
(10), while Jaeger et al. observed no significant association between the 3813A/G polymorphism and 
any of the obesity-related traits in a Brazilian population (16).  
In our study carriers of the AA genotype of the G1422A polymorphism were characterized by 
higher total fat, fat percentage, and percentage of android fat. Peeters et al. found that the CNR1 
A1422A genotype was significantly associated with higher WHR, WC, and fat mass percentage, but 
only in obese men. In obese women, no meaningful associations between CNR1 genotype and 
anthropometric parameters were found (9). Associations between the genotypes of the A4895G 
polymorphism and the investigated anthropometric variables were observedneither in our study nor in 
the studies of other authors (8). One explanation for the differences in results observed in the 
previously mentioned studies may relate to population differences. For example, in our study only 
white postmenopausal women were considered. Therefore generalization of these conclusions to other 
populations should be done with caution. 
What is more, body fat accumulation and body fat distribution result from the interaction of 
multiple genetic and lifestyle factors (1,19,20). 
 Clinical trials have shown that prolonged treatment with rimonabant, a pharmacological 
blocker of the CB1, not only effectively reduced body weight and abdominal fat, but also improved 
the metabolic profile in obese patients (13-16).  Thus we hypothesized that genetic variations at the 
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CNR1 locus might lead to an alteration of endocannabinoid signaling that in turn may lead to 
differences in body fat accumulation finally resulting in phenotypic expression of a metabolic 
disorder. However, no association between any of the polymorphic variants of CRN1 and metabolic 
parameters was observed in our study in contrast to the study of Aberle et al. (21). These workers 
observed that carriers of at least one A allele of the G1359A polymorphism in the CB1 gene following 
3 months of a low-fat caloric restricted diet lost more weight and reduced LDL cholesterol more than 
wild-type patients (21). They concluded that genetic polymorphisms associated with obesity may 
become relevant only under the condition of a low-calorie diet and that the presence of certain 
genotypes may be associated with a more beneficial response to obesity treatment.  
In summary, our study showed an association of variants of CNR1 with obesity-related 
phenotypes in Polish postmenopausal women. As CB1 is a drug target for obesity, pharmacogenetic 
receptor gene analysis may be of interest to identify the best responders to endocannabinoid blockade 
therapy for obesity. 
Conflict of interest 
Authors declare there are not any competing financial interests in relation to the work described. 
 10 
 
References 
 
1. Milewicz A, Tworowska U, Demissie M. Menopausal obesity - myth or fact? Climacteric 
2001; 4: 273-283  
2. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic 
exploitation. Nat Rev Drug Discov 2004; 3 :771–784 
3. Pagotto U, Vicennati V, Pasquali R. The endocannabinoid system and the treatment of 
obesity. Ann Med 2005; 37: 270–275  
4. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat 
Neurosci 2005; 8:585–589  
5. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the 
endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 
73–100  
6. Osei-Hyiaman D, Harvey-White J, Batkai S, Kunos G. The role of the endocannabinoid 
system in the control of energy homeostasis. Int J Obes 2006; 30(Suppl 1):S33–S38  
7. Zhang PW, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D et al. Human cannabinoid 
receptor 1: 5_ exons, candidate regulatory regions, polymorphisms, haplotypes and 
association with polysubstance abuse. Mol Psychiatry 2004; 9: 916–931  
8. Russo P, Strazzullo P, Cappuccio FP, Tregouet DA, Lauria F, Loguercio M et al. 
Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with 
obesity phenotypes in men. J Clin Endocrinol Metab 2007; 92: 2382-2386 
9. Peeters A, Beckers S, Mertens I, Van Hul W, Van Gaal L. The G1422A variant of the 
cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men. 
Endocrine 2007; 31:138-141  
10. Benzinou M, Chèvre JC, Ward KJ, Lecoeur C, Dina C, Lobbens S et al. 
Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass 
index in European populations. Hum Mol Genet 2008; 17:1916-1921 
 11 
 
11. Greenfield JR, Samaras K, Chisholm DJ. Insulin resistance, intra-abdominal fat, 
cardiovascular risk factors, and androgens in healthy young women with type 1 diabetes 
mellitus.  J Clin Endocrinol Metab 2002; 87:1036-1040 
12. Wajchenberg BL. Subcutaneous and visceral  adipose tissue: their relation to the metabolic 
syndrome. End Rev 2000; 21:637-738 
13. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO-Europe Study Group. 
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and 
cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe 
study. Lancet 2005; 365:1389–1397 
14. Despres JP, Golay A, Sjostrom L, Rimonabant in Obesity-Lipids Study Group. Effects of 
rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 
2005; 353:2121–2134  
15. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study 
Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic 
risk factors in overweight or obese patients: RIO-North America: a randomized controlled 
trial. JAMA 2006; 295:761– 775 
16. Jaeger JP, Mattevi VS, Callegari-Jacques SM, Hutz MH. Cannabinoid type-1 receptor 
gene polymorphisms are associated with central obesity in a Southern Brazilian population. 
Dis Markers 2008; 25:67-74 
17. Gazzerro P, Caruso MG, Notarnicola M, Misciagna G, Guerra V, Laezza C et al. 
Association between cannabinoid type-1 receptor polymorphism and body mass index in a 
southern Italian population. Int J Obes (Lond) 2007; 31:908-912 
18. Lieb W, Manning AK, Florez JC, Dupuis J, Cupples LA, McAteer JB et al. Variants in 
the CNR1 and the FAAH genes and adiposity traits in the community. Obesity 2009; 17:755-
760 
19. Siani A, Strazzullo P. Tackling the genetic bases of metabolic syndrome: a realistic objective? 
Nutr Metab Cardiovasc Dis 2006; 5:309–312 
 12 
 
20. Blakemore AIF, Froguel P. Is Obesity Our Genetic Legacy? J Clin Endocrinol Metab 2008;  
93: S51–S56 
21. Aberle J, Flitsch J, Beck NA, Mann O, Busch P, Peitsmeier P et al. Genetic variation 
may influence obesity only under conditions of diet: analysis of three candidate genes. Mol 
Genet Metab 2008; 95: 188-191 
TABLE 1. 
The specific pairs of primers used for the amplification of CNR1 gene (347-bp and 346-bp). 
 SNP Forward primer  Revers primer  
1 A3813G 5'-GATGAAGGCTCAGGGTGCTAGAGG-3' 5'-TAGTGCTGTCAGCCCCATTGTCCC-3' 
2 G1422A 5'-CCTGCGACACGCTTTCCGGA-3' 5'-CTGCCAGGGAGGCATCAGGC-3' 
3 A4895G 5'-GAGACCACCCATATCATGCACACA-3' 5'-AACTCTGATCCCCAGTAGGCCTAG-3' 
TABLE 2. Anthropometric variables according to the CNR1 A3813G alleles in Polish postmenopausal women.  
 
Except for number, values are mean ± SD. p value for ANOVA 
 
 
TABLE 3. Metabolic variables according to the CNR1 A3813G alleles in Polish postmenopausal women 
 AA AG + GG p value 
No. (%) 241 (70%) 105 (30%)  
Age (yr.) 55.59 ± 2.68 55.15 ± 2.84 0.167 
Body mass (kg) 70.12 ± 11.31 71.74 ± 12.87 0.242 
Height (m) 160.33 ± 5.28 160.50 ± 5.63 0.779 
BMI (kg/m2) 27.33 ± 4.57 27.92 ± 5.24 0.296 
WC (cm) 87.13 ± 11.37 88.67 ± 12.21 0.281 
Total fat (g) 25948.29 ± 7479.67 27323.31 ± 8394.61 0.174 
Fat (%) 37.38 ± 4.87 38.20 ± 5.67 0.220 
Android deposit (g) 2472.64 ± 1300.53 2971.78 ± 1655.08 0.007 
Android deposit (%) 35.66 ± 7.63 37.59 ± 8.45 0.062 
Gynoid deposit (g) 6639.84 ± 1759.95 6543.93 ± 2507.68 0.716 
 AA AG + GG p value 
No. (%) 241 (70%) 105 (30%)  
Glucose [mg/dl] 87.68 ± 9.57 89.28 ± 11.97 0.193 
Total cholesterol [mg/dl] 244.71 ± 40.85 246.42 ± 48.02 0.735 
HDL cholesterol [mg/dl] 70.80 ± 17.57 69.74 ± 16.33 0.604 
LDL cholesterol [mg/dl] 153.42 ± 39.27 153.73 ± 40.91 0.947 
Triglycerides [mg/dl] 106.02 ± 47.54 114.86 ± 52.86 0.129 
Insulin [µIU/ml] 6.38 ± 4.04 6.93 ± 4.69 0.279 
FIRI 1.23 ± 0.88 1.35 ± 1.07 0.266 
 
Except for number, values are mean ± SD. p value for ANOVA 
 
TABLE 4. Anthropometric variables according to the CNR1 G1422A alleles in Polish postmenopausal women.  
 
Except for number, values are mean ± SD. p value for ANOVA 
 
 
TABLE 5. Metabolic variables according to the CNR1 G1422A alleles in Polish postmenopausal women 
 AA AG + GG p value 
No. (%) 244 (70%) 104 (30%)  
Age (yr.) 54.93 ± 2.71 55.44 ± 2.73 0.465 
Body mass (kg) 75.18 ± 15.29 70.19 ± 11.52 0.097 
Height (m) 162.93 ± 6.19 160.12 ± 5.13 0.035 
BMI (kg/m2) 28.25 ± 5.08 27.44 ± 4.77 0.511 
WC (cm) 91.12 ± 13.51 87.32 ± 11.48 0.201 
Total fat (g) 31587.72 ± 9161.28 26078.26 ± 7552.14 0.019 
Fat (%) 40.51 ± 5.66 37.51 ± 4.99 0.052 
Android deposit (g) 3185.51 ± 1454.89 2604.58 ± 1433.83 0.189 
Android deposit (%) 40.86 ± 9.73 36.09 ± 7.70 0.047 
Gynoid deposit (g) 7893.93 ± 2422.82 6522.90 ± 1963.45 0.025 
 AA AG + GG p value 
No. (%) 244 (70%) 104 (30%)  
Glucose [mg/dl] 85.73 ± 6.83 88.36 ± 10.61 0.342 
Total cholesterol [mg/dl] 244.80 ± 47.84 244.93 ± 43.46 0.990 
HDL cholesterol [mg/dl] 71.26 ± 15.80 70.25 ± 17.24 0.824 
LDL cholesterol [mg/dl] 151.46 ± 46.28 153.34 ± 39.65 0.858 
Triglycerides [mg/dl] 110.40 ± 45.09 109.14 ± 49.47 0.923 
Insulin [µIU/ml] 7.19 ± 3.78 6.65 ± 4.32 0.625 
FIRI 1.26 ± 0.83 1.30 ± 0.96 0.883 
 
Except for number, values are mean ± SD. p value for ANOVA 
 
